CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞的前行之路
英文原题：The road ahead for chimeric antigen receptor T cells.
查看英文原题
The road ahead for chimeric antigen receptor T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法是一种创新的免疫治疗形式，在B细胞恶性肿瘤患者中已显示出显著且持久的缓解。多年来，该领域在理解CAR-T 细胞疗法的成功与挑战方面取得了重大进展。在本综述中，我们概述了CAR-T 细胞疗法在临床中的现状。我们详细阐述了当前的挑战，包括患者可及性、CAR-T 相关毒性、肿瘤异质性、CAR-T 细胞迁移、肿瘤微环境以及不同的CAR-T 细胞命运。针对每一项挑战，我们回顾了经验教训、潜在解决方案，并概述了未来发展的方向。最后，我们讨论了工程化细胞治疗领域如何向实体瘤及癌症以外的其他疾病治疗拓展。
展开英文摘要原文
Chimeric antigen receptor T (CART) cell therapy is an innovative form of immunotherapy that has shown remarkable and long-term responses in patients with B-cell malignancies. Over the years, the field has made significant progress in our understanding of the successes and challenges associated with CART cell therapy. In this review, we provide an overview of the current state of CART cell therapy in the clinic.
We detail current challenges including patient access, CART-associated toxicity, tumor heterogeneity, CART cell trafficking, the tumor microenvironment, and different CART cell fates. With each challenge, we review lessons learned, potential solutions and outline areas for future development.
Finally, we discuss how the field of engineered cell therapy is moving into the treatment of solid tumors and other diseases beyond cancer.
论文信息
- 作者
- Stewart CM、Siegler EL、Kenderian SS
- 单位
- T Cell Engineering, Mayo Clinic, Rochester, MN, United States.United States
- 文献类型
- 综述
- 期刊
- Journal of immunology (Baltimore, Md. : 1950)2025 Jul 1
- 原文标识
- PubMed 40209174 · DOI 10.1093/jimmun/vkaf047